[177Lu]Lu-PSMA-597 dose-intensification trial OPTIMAL-PSMA aims for superior PSA response in mCRPC.
A Phase 2, Open-Label, Randomized Controlled Trial Evaluating Safety and Efficacy of Dose-Intensified Versus Standard Dosing Regimens of [177Lu]Lu-PSMA-597 in mCRPC (OPTIMAL-PSMA).
Abstract
OPTIMAL-PSMA, a Phase 2 RCT, evaluates if dose-intensified [177Lu]Lu-PSMA-597 improves PSA response in mCRPC compared to standard dosing.